Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
出版年份 2021 全文链接
标题
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-09-07
DOI
10.1016/s1470-2045(21)00404-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immune checkpoint inhibitors in mesothelioma: a turning point
- (2021) Giovanni Luca Ceresoli et al. LANCET
- First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
- (2021) Paul Baas et al. LANCET
- Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
- (2020) Y. Metaxas et al. ANNALS OF ONCOLOGY
- Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study
- (2020) Diego Cortinovis et al. Clinical Lung Cancer
- A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
- (2020) S. Popat et al. ANNALS OF ONCOLOGY
- Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
- (2020) Maria Pagano et al. Cancers
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
- (2019) Giorgio V Scagliotti et al. Lancet Respiratory Medicine
- Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma
- (2019) Anne Tsao et al. SEMINARS IN ONCOLOGY
- Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Hedy L. Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial
- (2018) Vanesa Gregorc et al. LANCET ONCOLOGY
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma
- (2018) Paolo A. Zucali Journal of Thoracic Disease
- Current and Future Management of Malignant Mesothelioma : A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation
- (2018) Anne S. Tsao et al. Journal of Thoracic Oncology
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
- (2015) Lee M Krug et al. LANCET ONCOLOGY
- Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma
- (2014) Marjorie G. Zauderer et al. LUNG CANCER
- Ramucirumab: a novel antiangiogenic agent
- (2013) Roopma Wadhwa et al. Future Oncology
- Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study
- (2013) Wieneke A Buikhuisen et al. LANCET ONCOLOGY
- Vascular Endothelial Growth Factor Receptor 2 as a Marker for Malignant Vascular Tumors and Mesothelioma
- (2012) Markku Miettinen et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
- (2011) Giovanni L. Ceresoli et al. LUNG CANCER
- Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey
- (2011) P.A. Zucali et al. LUNG CANCER
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
- (2009) Axel Grothey et al. Nature Reviews Clinical Oncology
- Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice
- (2008) S. P. Dineen et al. CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started